Form 4: Lisata Therapeutics Director Acquires Restricted Stock Units
SEC Form 4 Filing
Cynthia Louise Flowers, a director at Lisata Therapeutics, acquired 15,789 restricted stock units, which will vest on January 9, 2026.
Summary
- Cynthia Louise Flowers, a director of Lisata Therapeutics, acquired 15,789 restricted stock units on January 9, 2025.
- These restricted stock units were granted under the company's 2018 Equity Incentive Compensation Plan.
- The units will vest on January 9, 2026.
- Following the transaction, Ms. Flowers beneficially owns 64,990 shares, which includes the unvested restricted stock units.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction, which is generally positive as it shows director engagement and alignment with company goals. There are no negative implications.
Positives
- The acquisition of restricted stock units by a director signals confidence in the company's future performance.
- The vesting period of one year aligns the director's interests with the long-term success of the company.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.
Comparison to Industry Standards
- The granting of restricted stock units to directors is a common practice in publicly traded companies as part of their compensation and incentive programs.
- The vesting period of one year is also a typical timeframe for such grants, aligning the director's interests with the company's performance over the medium term.
- Other companies in the biotechnology sector, such as Amgen and Gilead, also use similar equity-based compensation plans for their directors and executives.
Stakeholder Impact
- The acquisition of restricted stock units by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 01/09/2025 | Date of the transaction where restricted stock units were acquired. |
| 01/09/2026 | Vesting date for the restricted stock units. |
| 01/13/2025 | Date of the signature of the report. |
Keywords
restricted stock units, insider trading, equity compensation, director, Lisata Therapeutics, LSTA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.